바이오인프라

199730KOSDAQ자연과학 및 공학 연구개발업

53.0 / 100

Reference Date: 2026-04-13

Financial Score19.5 / 40

News Sentiment12.5 / 25

Momentum11.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Slightly up 1.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

BioInfral is a CRO established in 2007, specializing in bioequivalence testing for generic drugs, Phase I clinical trials for improved drugs, approval clinical trials, immunoassays, and pharmaceutical quality inspections. The company operates multiple business units, including PK, Clinical, Immunoassay, and Testing, offering diverse services such as drug interaction studies, clinical trial management, biomarker analysis, and stability testing.

Number of Employees

141people

Average Salary

47.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 120.074.0Point

PBR

1.20Industry Average 3.827.0Point

Half of industry avg (excellent)

ROE

-41.45Industry Average -32.113.5Point

In line with industry avg

Debt Ratio

4.88Industry Average 7.525.0Point

Lower than industry avg (good)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.9% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼257.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -15.6% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (24%)

Current 4,065Won52-week high 6,51052-week low 3,260

1-month return3.0Point

1m 1.62% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식매수선택권부여에관한신고2026-03-25
Neutral정기주주총회결과2026-03-25
Neutral[기재정정]주식매수선택권부여에관한신고2026-03-19
Neutral사업보고서 (2025.12)2026-03-17
Neutral감사보고서제출2026-03-16